SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of...
SQZ Biotechnologies reported revenue of $21.03 million for fiscal year 2022, down 22.4% from fiscal year 2021, and net income of -$79.46 million. In Q3 2023 (the quarter ended September 30, 2023) revenue was $0, down 100.0% from a year before. Its market capitalization was $707,787 as of February 5, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2022; market data as of February 5, 2026.
No profile data available.